Patents by Inventor Johny BERTELS

Johny BERTELS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENTS OF PROSTATE CANCER WITH COMBINATIONS OF ABIRATERONE ACETATE AND NIRAPARIB
    Publication number: 20230226080
    Abstract: The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.
    Type: Application
    Filed: May 7, 2021
    Publication date: July 20, 2023
    Inventors: Thomas Ronald A. QUINTEN, Urbain Alfons C. DELAET, Philip Erna H. HEYNS, Tatiana MARCOZZI, Johny BERTELS, Katrien LUYTEN, Kaustubh Ramesh TAMBWEKAR, Angela LOPEZ-GITLITZ, Paul J. A. HARTMAN KOK
  • PHARMACEUTICAL FORMULATIONS OF ABIRATERONE ACETATE AND NIRAPARIB
    Publication number: 20230226081
    Abstract: The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.
    Type: Application
    Filed: May 7, 2021
    Publication date: July 20, 2023
    Inventors: Thomas Ronald A. QUINTEN, Urbain Alfons C. DELAET, Philip Erna H. HEYNS, Tatiana MARCOZZI, Johny BERTELS, Katrien LUYTEN, Kaustubh Ramesh TAMBWEKAR, Angela LOPEZ-GITLITZ, Paul J. A. HARTMAN KOK
  • TREATMENT OF PROSTATE CANCER WITH A COMBINATION OF ABIRATERONE ACETATE AND NIRAPARIB
    Publication number: 20230218640
    Abstract: The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.
    Type: Application
    Filed: May 7, 2021
    Publication date: July 13, 2023
    Inventors: Thomas Ronald A. QUINTEN, Urbain Alfons C. DELAET, Philip Erna H. HEYNS, Tatiana MARCOZZI, Johny BERTELS, Katrien LUYTEN, Kaustubh Ramesh TAMBWEKAR, Angela LOPEZ-GITLITZ, Paul J. A. HARTMAN KOK
  • Anticancer Compositions
    Publication number: 20190216829
    Abstract: The present invention concerns pharmaceutical formulations of abiraterone acetate and ARN-509, which can be administered to a mammal, in particular a human, suffering from an androgen receptor (AR)-related disease or condition, in particular cancer, more in particular prostate cancer, including but not limited to castration-resistant prostate cancer, metastatic castration resistant prostate cancer, chemotherapy-naive metastatic castration resistant prostate cancer, biochemically relapsed hormone sensitive prostate cancer, or high-risk, non-metastatic castration-resistant prostate cancer. In one aspect, these formulations comprise abiraterone acetate and a solid dispersion of ARN-509 and a polymer selected from HPMCAS, a poly(meth)acrylate copolymer, and mixtures thereof. In one aspect, these formulations comprise a granulate of abiraterone acetate and a solid dispersion of ARN-509 and a polymer selected from HPMC AS, a poly(meth)acrylate copolymer, and mixtures thereof.
    Type: Application
    Filed: May 16, 2017
    Publication date: July 18, 2019
    Inventors: Johny BERTELS, Jurgen MENSCH